The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InGan & Lee Pharmaceuticals (SSE: 603087) announced that its investigative once-weekly basal insulin injection, GZR4, successfully met primary endpoints in two pivotal Phase 3 clinical trials. The trials, named SUPER-1 and SUPER-2, were designed to evaluate the efficacy and safety of the long-acting insulin compared to daily alternatives. Achieving these milestones marks a significant step toward regulatory approval and commercialization for the biotech firm. By reducing injection frequency from daily to weekly, GZR4 aims to significantly improve patient compliance and quality of life for those managing diabetes. The positive clinical data is expected to bolster investor confidence in the company's research and development pipeline. This development positions Gan & Lee as a strong competitor in the global diabetes treatment market.